Urinary Bone Turnover Markers as Target Indicators for Monitoring Bisphosphonate Drug Treatment in the Management of Osteoporosis

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|19|5|451-459

ISSN： 1389-4501

Source： Current Drug Targets, Vol.19, Iss.5, 2018-03, pp. : 451-459

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biochemical Markers of Bone Turnover in the Clinical Development of Drugs for Osteoporosis and Metastatic Bone Disease: Potential Uses and Pitfalls

By Cremers Serge   Garnero Patrick  

Drugs, Vol. 66, Iss. 16, 2006-01 ,pp. : 2031-2058

Adis International

Access to resources Recommend Favorite

Effects of Combined Treatment with Calcitriol plus Alendronate on Bone Mass and Bone Turnover in Postmenopausal Osteoporosis: Two Years of Continuous Treatment

By Frediani B.   Allegri A.   Bisogno S.   Marcolongo R.  

Clinical Drug Investigation, Vol. 15, Iss. 3, 1998-03 ,pp. : 235-244

Adis International

Access to resources Recommend Favorite

Bisphosphonate Treatment of Lytic Bone Metastases

By Lipton A.  

Drugs & Aging, Vol. 14, Iss. 4, 1999-04 ,pp. : 241-246

Adis International

Access to resources Recommend Favorite

Safety of Long-Term Bisphosphonate Therapy for the Management of Osteoporosis

By Lewiecki E. Michael  

Drugs, Vol. 71, Iss. 6, 2011-04 ,pp. : 791-814

Adis International

Access to resources Recommend Favorite

Effects of Statins on Bone Markers, Bone Mineral Density and Fractures. Possible Role in Osteoporosis Treatment

By  

Current Pharmaceutical Analysis, Vol. 2, Iss. 2, 2006-05 ,pp. : 161-168

Bentham Science Publishers

Access to resources Recommend Favorite